04 December 2017 | News
Xultophy(R) Offers Greater Blood Sugar and Body Weight Reductions in People with Type 2 Diabetes, Compared to IGlarLixi
The Comparison between Xultophy and IGlarLixi is done indirectly in people with type 2 diabetes who struggle to achieve desired blood sugar targets with basal insulin alone.
The result illustrates that the treatment with Xultophy® (insulin degludec/liraglutide) provides statistically significant greater reductions in blood sugar levels and body weight compared with IGlarLixi (insulin glargine U100/lixisenatide).
"In the absence of a head-to-head trial between Xultophy® and IGlarLixi, the solid methodology of this indirect comparison, where we adjusted for key differences between study designs and patient populations; allows us to conclude that Xultophy® can deliver greater reductions in the overall blood sugar levels and weight for people with type 2 diabetes who are uncontrolled on basal insulin, compared to IGlarLixi," said lead study author Professor Marc Evans of University Hospital, Llandough in Cardiff, UK.
This analysis is based on published data from individual clinical trials which involved over 700 adults living with type 2 diabetes.
This indirect comparison provides evidence for estimating the relative efficacy and safety of Xultophy® versus IGlarLixi in people with type 2 diabetes uncontrolled on basal insulin.
The outcomes came up with 0.44% greater reduction of their overall blood sugar levels (HbA1c), and a 1.42 kg greater weight loss when treated with Xultophy®, compared to those treated with IGlarLixi, at similar doses of insulin.
Additionally, the analysis found a higher likelihood of reaching target blood sugar levels (HbA1c <7%) with Xultophy®, compared to IGlarLixi.